QATCH Technologies is an RTP-based life-science instrumentation company and a Duke University spin-out, founded in 2016. QATCH Technologies aims to change injectable protein drug development by its small volume and rapid formulation characterization tool. Many protein molecules cannot be injected due to high viscosity. The existing viscometers consume large volumes of formulations when testing injectability and manufacturability, which makes it impossible to perform this test earlier and still very costly after scaling up production as valuable pharmaceutical material is consumed in the process. QATCH's nanovisQ uses only a fraction of a drop of the formulation to identify injectability and hence positioned to de-risk hundreds of millions dollars in a project by early-stage testing. Currently, QATCH has 5 full-time employees, an exclusive license to the IP for the core-technology and has filed IP on this specific application. QATCH has raised close to $3MM through SBIR grants from NSF, NIH, and NIST for R&D. In addition, QATCH has been performing fee-for-service contract work for biopharma using the nanovisQ technology.